Is Bio-Rad Laboratories, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Bio-Rad Laboratories, Inc. has moved from attractive to fair. Based on the current metrics, the company appears to be fairly valued. The P/E ratio stands at 5, significantly lower than the industry average, while the EV to EBITDA ratio is 10.62, indicating a reasonable valuation relative to earnings before interest, taxes, depreciation, and amortization. Additionally, the PEG ratio is notably low at 0.07, suggesting potential undervaluation based on growth expectations.
In comparison to its peers, Bio-Rad's P/E ratio of 16.20 is lower than Hologic, Inc. at 21.83 and QIAGEN NV at 24.20, both of which are also considered fairly valued. However, it is worth noting that The Cooper Companies, Inc. is categorized as expensive with a P/E of 34.28. Despite a recent strong performance with a 1-week return of 4.13% compared to the S&P 500's 1.70%, Bio-Rad has underperformed over longer periods, with a year-to-date return of -5.63% versus the S&P 500's 13.30%. This trend suggests that while the stock may be fairly valued now, it has struggled to keep pace with broader market returns.